March 6th 2024
In the third part of this video series, Susan Cantrell, CEO of AMCP, discusses the impact of drug prices on patient adherence with Managed Healthcare Executive.
Drug benefit clause not easy to repeal
January 1st 2007Washington, D.C.-Although campaigning Democrats promised to repeal the "non-interference" clause in the Medicare drug benefit, making such a change may not be all that easy. Democrats could push through a straight repeal of the current provision that prevents the federal government from directly negotiating drug prices with pharmaceutical companies. Such a move, however, would not necessarily alter the program under a Republican administration that believes private drug plans can negotiate prices better than bureaucrats.
Read More
Seniors in Part D donut hole unlikely to have gap coverage
January 1st 2007Although as many as 48% of seniors were subject to some type of drug-coverage deficiency in 2006, only an estimated 4 million of the 22.5 million enrolled in Medicare drug plans were actually expected to hit the infamous donut hole. There could still be financial woes, however, for the 10.8 million Medicare beneficiaries who at least have the potential for out-of-pocket costs in the donut hole gap because they do not qualify for a subsidy, are not covered outside Part D, or did not pay for enhanced gap coverage.
Read More